New hope for myeloma patients with kidney failure: drug combo aims to restore kidney function
NCT ID NCT07085728
First seen May 17, 2026 · Last updated May 23, 2026 · Updated 1 time
Summary
This study compares two treatment combinations for people newly diagnosed with multiple myeloma who also have kidney failure. One group gets the standard drugs (cyclophosphamide, bortezomib, dexamethasone), while the other gets daratumumab plus bortezomib and dexamethasone. The goal is to see if adding daratumumab improves kidney function more than the usual approach. 74 adults are participating, and they will be followed for up to 10 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alaska Oncology and Hematology LLC
Anchorage, Alaska, 99508, United States
Conditions
Explore the condition pages connected to this study.